- NewLimit’s $435M megaround; Lilly’s busy dealmaking week<figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…BioPharma Dive · 1mo ago↗ source
- Lilly, Ascidian link up in RNA exon editing pact<figure><div><img src="https://imgproxy.divecdn.com/bKYI5AaRrb25hqL3nHK7n6AzFsw0Gt03r4zGyJwaB84/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjkxMjU5MjM3LmpwZ…BioPharma Dive · 1mo ago↗ source
- Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial<figure><div><img src="https://imgproxy.divecdn.com/hbk6XyVan10rkkgfacDKrllv7E86oIa8ejytDOpzCw8/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTg0MTk0NzE1LmpwZ…